¿Aún no está registrado?
Información relevante

Consulte los artículos y contenidos publicados en este medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación

Máxima actualización

Esté informado en todo momento gracias a las alertas y novedades

Promociones exclusivas

Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados

Crear Mi cuenta
Buscar en
Reprodução & Climatério
Toda la web
Inicio Reprodução & Climatério Outcomes of GnRH agonist triggering in assisted reproductive technology: a syste...
Información de la revista
Vol. 32. Núm. 2.
Páginas 71-152 (Mayo - Agosto 2017)
Descargar PDF
Más opciones de artículo
Vol. 32. Núm. 2.
Páginas 71-152 (Mayo - Agosto 2017)
Review article
DOI: 10.1016/j.recli.2016.07.003
Open Access
Outcomes of GnRH agonist triggering in assisted reproductive technology: a systematic review
Resultados da maturação oocitária final com agonistas do GnRH nos ciclos de reprodução assistida: uma revisão sistemática
Luciana Beatriz Mendes Gomesa,
Autor para correspondencia

Corresponding author.
, Mário Henrique Bitar Siqueiraa, Eduardo Camelo de Castrob
a Pontifícia Universidade Católica de Goiás, Goiânia, GO, Brazil
b Pontifícia Universidade Católica de Goiás, Ambulatório de Infertilidade, Goiânia, GO, Brazil
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Texto completo
Descargar PDF
Figuras (1)
Tablas (1)
Table 1. Outcomes described in the systematic review.

To make a review of studies that assessed the outcomes of GnRH agonist oocyte triggering in comparison with hCG in prevention of ovarian hyperstimulation syndrome and pregnancy rates.


A systematic review of studies presented in the following database: PUBMED, Lilacs and Scielo submitted from January 2005 to October 2015. The keywords were ovulation induction, ovarian hyperstimulation syndrome and gonadotropin releasing hormone.


One hundred fifty-four articles were found. From these, twelve studies were completely analyzed. Eight fulfilled the inclusion criteria and one was included after the bibliographic review of the previous ones. From these nine submitted articles, two are retrospective and the others are prospective.


The use of GnRH agonist for oocyte triggering was comparable with hCG and showed low frequency of ovarian hyperstimulation syndrome.

Gonadotropin-releasing hormone
Ovarian hyperstimulation syndrome
Pregnancy rate

Fazer uma revisão dos estudos que avaliaram os desfechos do agonista de GnRH no ovócito em comparação com hCG na prevenção da síndrome de hiperestimulação ovariana e nas taxas de gestação.


Revisão sistemática de estudos presentes nos seguintes bancos de dados: Pubmed, Lilacs e Scielo, apresentados de janeiro de 2005 até outubro de 2015. As palavras-chave foram indução da ovulação, síndrome de hiperestimulação ovariana e hormônio liberador de gonadotropina.


Foram localizados 154 artigos; 12 foram integralmente analisados; oito preenchiam os critérios de inclusão; um foi incluído depois da revisão bibliográfica dos estudos precedentes. Dentre esses nove artigos apresentados, dois são retrospectivos e os demais são prospectivos.


O uso do agonista de GnRH para a indução do ovócito foi comparável ao hCG, demonstrou baixa frequência de síndrome de hiperestimulação ovariana.

Hormônio liberador de gonadotropina
Síndrome de hiperestimulação ovariana
Taxa de gestação
Texto completo

The gonadotropin releasing hormone (GnRH) agonist has been used for triggering final oocyte maturation in in vitro fertilization (IVF) for a few years. The first authors to document this practice were Gonan and Casper, in 1990, obtaining in their study with eighteen patients, oocyte quality and quantity outcomes similar to hCG triggering.1 However, It was only with the rise of GnRH antagonist protocol that its use was truly propagated in the beginning of this century.2,3

The prevention of ovarian hyperstimulation syndrome (OHSS), fearsome iatrogenic complication of human reproduction techniques, became the main indication of this type of triggering. Several studies showed incidence's reduction, mostly because of the early induction and short duration of LH surge.4–6

The aim of this study is to review the GnRH agonist triggering outcomes in comparison with hCG in the prevention of ovarian hyperstimulation syndrome and in pregnancy rates.

Materials and methods

The keywords used for the construction of this article were: ovulation induction, ovarian hyperstimulation syndrome and gonadotropin releasing hormone. The following database: Pubmed, Lilacs and Scielo were analyzed. The articles published from January of 2005 to October of 2015 in Portuguese, Spanish and English were selected by two researchers independently. If disagreement a third researcher was consulted. The inclusion and exclusion criteria were based on the main systematic reviews about the subject available. The inclusion criteria were: studies using GnRH agonist (GnRHa) for triggering that described its outcomes in pregnancy rates and/or OHSS, women with age between 18 and 40 years, BMI between 18 and 35kg/m2, non-smokers and with ovarian reserve of 3 or more antral follicles. It was excluded from this review, women that had any uterine pathology or malformation.

One hundred and fifty four published articles were found considering the keywords and filters used in association. After their abstracts reading, twelve articles were selected for posterior full read. From these, nine fit the inclusion criteria. The method was described in the form of a fluxogram represented in Fig. 1. As a systematic review, approval of the local Research Ethics Committee wasn’t necessary.

Fig. 1.

Fluxogram of the methodology used in this systematic review.


The articles data were summed up in Table 1 for comparative analysis. From 9 selected studies, seven were prospective including randomized clinical trials and cohorts. The oldest paper is from 2005 by Kolibianakis et al. fulfilled in two human reproduction centers, one in Belgium and the other in Germany whilst the most recent is from 2014, by Decleer et al. The highest population assayed was in Spain with 1171 women and the smallest in Cyprus with only 44 patients.

Table 1.

Outcomes described in the systematic review.

References  Year  Country  Design  Population  OHSSImplantation RatePregnancy rate
          GnRHa  hCG  GnRHa  hCG  GnRHa  hCG 
Kolibianakis et al.  2005  Belgium/Germany  Prospective  106  Absent  Absent  6.8%  22.6%  5.6%/2.9  41.7%/16.7% 
Bodri et al.  2009  Spain  Retrospective  1171  Absent  13 cases  25.9%  29.1%  38.8%  42.1% 
Melo et al.  2009  Spain  Prospective  100  Absent  8 cases  30.4%  27.1%  52%  58% 
Sismanoglu et al.  2009  Cyprus  Prospective  44  Absent  4 cases  32.93%  3653%  6881%  69% 
Griesinger et al.a  2011  Germany  Prospective  51  4 cases  Absent  UnquotedUnquoted
Tal Imbar et al.  2012  Israel  Prospective  110  Absent  Absent  36%  Unquoted  52%  Unquoted 
Iliodromiti et al.  2013  Vietnam  Retrospective  620  1 case  18 cases  14.2%  16.6%  30%  30% 
Humaidan et al.b  2013  Denmark  Prospective  384  2 cases  2 cases  35.5%  29.5%  34.6%  28.6% 
Decleer et al.b  2014  Belgium  Prospective  120  Absent  Absent  22%  34%  31.1%  44.1% 

GnRHa, gonadotropin releasing hormone antagonis; hCG, human chorionic gonadotropin; OHSS, ovarian hyperstimulation síndrome.


Study non-comparative with hCG.


Studies show a comparison between hCG with GnRH agonist and isolated hCG.


The GnRH agonist use for triggering oocyte final maturation was propagated as prevention to ovarian hyperstimulation syndrome for its effect in LH surge. It has shorter half-life than hCG stimulation and decreases the vascular endothelial factor growth (VEFG1) production which is the main developer of the syndrome.7

Kolibianakis et al.,8 in his randomized clinical trial, with 106 women in two European centers found in one of them statistic significant decrease (p=0.012) in pregnancy rate in the agonist use group (5.6% vs 41.7%) and a clear reduction, though not statistic significant, in the same group in the second center (2.9% vs 16.7%). Higher implantation rate was also described in the hCG group and no OHSS case was observed in neither one. Thus, no advantaged of the agonist was noted in the study.

However, the others screened studies demonstrated better results. Melo et al.9 made a prospective randomized cohort with 100 oocyte donors. No OHSS was found in the agonist group vs 16% in hCG group whilst the implantation, pregnancy and miscarriage rates were similar in both groups. Bodri et al.,10 in the same year, observed resembling results in his retrospective study with higher population (n=1171). Thirteen cases of OHSS (2.08%) in the hCG group and none in the agonist one was found and comparable outcomes between the groups as clinical pregnancy rates: 42.4% vs 38.8% and implantation rate: 29.1% vs 25.9%.

Simanoglu et al.,11 in a prospective study with oocyte donors, also found absence of the syndrome in the agonist group against 4 cases in the hCG one.

The association of final oocyte maturation with GnRH agonist and posterior freezing of oocyte and embryos (freeze-all strategy) is another method. Devroey12 proposed the possibility of an OHSS free-clinic with this approach in an opinion article. Griesinger et al.13 used this strategy to evaluate its results in a prospective multicenter study with OHSS high-risk women. Of 51 patients, 4 (7.9%) developed the syndrome, being one of them a severe case. Fatemi et al.14 also presented two clinical cases in United Arab Emirates and India who developed the severe case of the pathology with the use of the same approach, what demonstrates that an OHSS free-clinic is chimeric. Meanwhile, the pregnancy and live births rates were favorable with the protocol aforementioned.

Ilidromiti et al.15 compared the maturation with GnRH agonist associated with luteal phase support with progesterone in patients with higher risk of OHSS (n=363) with patients who received conventional dose of hCG (n=257) in a retrospective cohort. Only one case of OHSS occurred in the agonist group against 18 cases in the control group. Clinical pregnancy and live birth rates (30% and 29.7%, respectively) were similar whilst miscarriage rate was lower in the agonist group. Tal Imbar,16 in an observational prospective study, associated the use of agonist as trigger with luteal support with progesterone and freeze-all strategies and comparing with isolated use of agonist.

Humaidan et al.17 produced a prospective randomized study also comparing the use of hCG with GnRHa and luteal support, but with use of hCG, instead of progesterone. Three hundred and eighty four women were classified in higher and lower risk of OHSS (criteria used was the presence of more than 14 ovarian follicles). In the higher risk group (n=118), half of the patients received GnRHa with 1500U hCG support and the remaining received 5000U hCG alone. In the lower risk group the support was made with two doses of hCG. Before this conduct, none cases of OHSS were observed in the higher risk using GnRHa while two cases of the syndrome in the hCG alone group occurred (1.6%) and the reverse happened in the lower risk patients; two of the agonist group developed OHSS vs none in the hCG group. This strongly indicates the use of agonist only in higher risk patients. Other results as implantation, pregnancy and miscarriage rates resembled between the groups. Ilidromiti et al.,18 in the same year, through an multicenter retrospective study showed improvement of pregnancy rates with this luteal support with hCG but with OHSS occurrence (0.72%).

Decleer et al.,19 in his randomized clinical trial, compared the oocyte final maturation (GnRH +5000U hCG) with the use of hCG alone. In neither group OHSS occurred as implantation and pregnancy rates didn’t show statistic differences what didn’t justify the use of the combined medication.


The use of GnRH agonist for oocyte final maturation was comparable with hCG and some studies didn’t demonstrate statistic differences in implantation and pregnancy rates. Few studies that associate hCG with GnRHa didn’t demonstrate statistic differences in the rates aforementioned. The efficacy in decrease ovarian hyperstimulation syndrome also is clear when not associated with hCG. The association with freeze-all strategy promotes even higher reduction of the syndrome. However, its complete elimination remains a challenge.

Conflicts of interest

The authors declare no conflicts of interest.

Y. Gonen, H. Balakier, W. Powell, R.F. Casper.
Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization.
J Clin Endocrinol Metab, 71 (1990), pp. 918-922
F. Olivennes, J.S. Cunha-Filho, R. Fanchin, P. Bouchard, R. Frydman.
The use of GnRH antagonists in ovarian stimulation.
Hum Reprod Update, 8 (2002), pp. 279-290
A.T.A. Baris.
A brief history of GnRH agonist triggering and directions for future research.
JFIV Reprod Med Genet, 3 (2015), pp. e113
M. Banker, J. Garcia-Velasco.
Revisiting ovarian hyper stimulation syndrome: towards OHSS free clinic.
J Hum Reprod Sci, 8 (2015), pp. 13-17
S. Kol, J. Itskovitz-Eldor.
Gonadotropin-releasing hormone agonist trigger: the way to eliminate ovarian hyperstimulation syndrome – a 20 year experience. Seminars in reproductive medicine.
Semin Reprod Med, 28 (2010), pp. 500-505
P. Humaidan, S. Kol, E.G. Papanikolaou.
GnRH agonist for triggering of final oocyte maturation: time for a change of practice.
Hum Reprod Update, 17 (2011), pp. 510-524
D. Pietrowsky, L. Szabo, M. Sator, A. Just, C. Egarteer.
Ovarian hyperstimulation syndrome is correlated with a reduction of soluble VEGF receptor protein level and a higher amount of VEGF-A.
Hum Reprod, 27 (2012), pp. 196-199
E.M. Kolibianakis, A. Schutze-Mosgau, A. Schroer, A. vanSteirteghen, P. Devroey, K. Diedrich, et al.
A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
Hum Reprod, 20 (2005), pp. 2887-2892
M. Melo, C.E. Busso, J. Bellver, P. Alama, N. Garrido, N. Meseguer, et al.
GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study.
Reprod Healthcare, 19 (2009), pp. 486-492
D. Bodri, J. Guillén, A. Galindo, D. Mataró, A. Pujol, O. Coll.
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-trated oocyte donor cycles: findings of a large retrospective cohortstudy.
Fertil Steril, 91 (2009), pp. 365-371
A. Sismanoglu, H.I. Tekin, H.F. Erden, N.H. Ciray, U. Ulug, M. Bahceci.
Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial.
J Assist Reprod Genet, 26 (2009), pp. 251-256
P. Devroey, N.K. Polyzos, C. Blockeel.
An OHSS-Free Clinic by segmentation of IVF treatment.
Hum Reprod, 26 (2011), pp. 2593-2597
G. Griesinger, L. Schutz, T. Bauer, A. Broessner, T. Frambach, S. Kissler.
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a freeze-all strategy: a prospective multicentric study.
Fertil Steril, 95 (2011), pp. 2029-2033
H. Fatemi, B. Popovic-Todorovic, P. Humaidan, S. Kol, M. Banker, P. Devroey, et al.
Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and freeze-all approach in GnRH antagonist protocol.
S. Iliodromiti, V. Lan, H. Tuong, P. Tuan, P. Humaidan, S. Nelson.
Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study.
J Ovarian Res, 6 (2013), pp. 1-9
T. Imbar, S. Kol, F. Lossos, Y. Dolah, A. Hurwtz, R. Haimov-Kochma.
Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support.
Hum Reprod, 27 (2012), pp. 753-759
P. Humaidan, N.P. Polyzos, B. Alsbjerg, K. Erb, A.L. Mikkelsen, H.O. Elbaek, et al.
GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Hum Reprod, 28 (2013), pp. 2511-2521
S. Iliodromiti, C. Blockeel, K. Tremellen, R. Flaming, H. Tournaye, P. Humaidan, et al.
Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicenter study.
Hum Reprod, 28 (2013), pp. 2529-2536
W. Decleer, K. Osmanagaoglu, D. Seynhave, S. Kolibianakis, B. Tarlatzis, P. Devroey.
Comparison of hCG triggering versus hCG in combination with a GnRH agonist: a prospective randomized controlled trial.
Facts Views Vis Obstet Gyneacol, 6 (2014), pp. 203-209

End-of-course paper presented to Medicine Course at Pontifícia Universidade Católica de Goiás as parcial requirement to obtain the title of doctor. Advisor: Doctored Professor Eduardo Camelo de Castro.

Copyright © 2016. Sociedade Brasileira de Reprodução Humana
Opciones de artículo
es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.